Comments on "The severity of non-alcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota"

References

[1] Filozof C,Williams RN.Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway..Drugs2015;75:1373-92 PMCID:PMC4532706

[2] Singh S,Wang Z,Murad MH.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies..Clin Gastroenterol Hepatol2015;13:643-54.e1-9; quiz e39-40

[3] Boursier J.Nonalcoholic fatty liver disease and the gut microbiome..Clin Liver Dis2016;20:263-75

[4] Xie G,Liu P,Chen W,Hernandez BY,Dong B,Jia W.Distinctly altered gut microbiota in the progression of liver disease..Oncotarget2016;7:19355-66

[5] Yu J,Hu J,Wu C.The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background..Gastroenterol Res Pract2016;2016:2862173

[6] Nabavi S,Somi MH,Asghari-Jafarabadi M.Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease..J Dairy Sci2014;97:7386-93

[7] Boursier J,Barret M,Fizanne L,Guy CD,Rawls JF,Hunault G,Calès P.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota..Hepatology2016;63:764-75 PMCID:PMC4975935

[8] Dvorak K,Petrtyl J,Sroubkova R,Smid V,Bruha R.Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice - an exploratory case-control study..PLoS One2014;9:e111551 PMCID:PMC4211730

[9] Ferraioli G,Lissandrin R,Dal Bello B,Filice C.Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis..World J Gastroenterol2014;20:6626-31 PMCID:PMC4047351

[10] Fitzpatrick E.Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future..World J Gastroenterol2014;20:10851-63 PMCID:PMC4138464

[11] Nalbantoglu IL.Role of liver biopsy in nonalcoholic fatty liver disease..World J Gastroenterol2014;20:9026-37 PMCID:PMC4112884

[12] Zhang X,Tsuneda S.Bacterial metabolites directly modulate farnesoid X receptor activity..Nutr Metab (Lond)2015;12:48 PMCID:PMC4657204

[13] Paolella G,Pierri L,Di Stasi M.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease..World J Gastroenterol2014;20:15518-31 PMCID:PMC4229517

[14] Haque TR.Intestinal microbiota in liver disease..Best Pract Res Clin Gastroenterol2016;30:133-42

[15] Dugan CE,Park YK,Fernandez ML.Dairy consumption lowers systemic inflammation and liver enzymes in typically low-dairy consumers with clinical characteristics of metabolic syndrome..J Am Coll Nutr2016;35:255-61

[16] Imani Fooladi AA,Nourani MR,Alavian SM.Probiotic as a novel treatment strategy against liver disease.Hepat Mon2013;13:e7521 PMCID:PMC3631524

[17] Liu JE,Zhang J,Chen M.Probiotic yogurt effects on intestinal flora of patients with chronic liver disease..Nurs Res2010;59:426-32

[18] Takahashi Y,Inui H.Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis..World J Gastroenterol2015;21:3777-85 PMCID:PMC4385525

[19] Saez-Lara MJ,Ruiz-Ojeda FJ,Gil A.Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials..Int J Mol Sci2016;17:E928 PMCID:PMC4926461

[20] Shavakhi A,Firouzian H,Hekmatdoost A.Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial..Int J Prev Med2013;4:531-7 PMCID:PMC3733183

[21] Mei L,Li M,Liu Z,Zheng P.Co-administration of cholesterol-lowering probiotics and anthraquinone from Cassia obtusifolia L. ameliorate non-alcoholic fatty liver..PLoS One2015;10:e0138078 PMCID:PMC4573521